This MedLibrary.org supplementary page on Lisinopril is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Lisinopril
|
|
| Systematic (IUPAC) name | |
| 1-[6-amino-2- (1-carboxy-3-phenyl-propyl) amino-hexanoyl]pyrrolidine- 2-carboxylic acid dihydrate | |
| Identifiers | |
| CAS number | |
| ATC code | C09 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H31N3O5 |
| Mol. mass | 405.488 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | approx. 25%, but wide range between individuals (6 to 60%) |
| Protein binding | 0 |
| Metabolism | None |
| Half life | 12 hours |
| Excretion | Eliminated unchanged in Urine |
| Therapeutic considerations | |
| Pregnancy cat. |
D - teratogenic |
| Legal status |
℞ Prescription only |
| Routes | ? |
Lisinopril (lye-SIN-o-pril) is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure, heart attacks and also in preventing renal and retinal complications of diabetes. It has been compared with omapatrilat which is of similar function.
Historically, lisinopril was the third ACE inhibitor, after captopril and enalapril, and was introduced into therapy in the early 1990s.[1] Lisinopril has a number of properties that distinguish it from other ACE inhibitors: it is hydrophilic, has long half-life and tissue penetration and is not metabolized by the liver.
Contents |
Pharmacology
Lisinopril is the lysine-analog of enalapril. Unlike other ACE inhibitors, lisinopril is not a prodrug and is excreted unchanged in the urine. In cases of overdosage, it can be removed from circulation by dialysis.
Clinical use
Its indications, contraindications and side effects are as those for all ACE inhibitors. Its long half-life allows for once a day dosing which aids patient compliance. The usual daily dose in all indications ranges from 2.5 mg in sensitive patients to 40 mg. Some patients have been treated with 80 mg daily and have tolerated this high dose well. Lower dosages must be used in patients with higher grade renal impairment (glomerular filtration rate (GFR) lower than 30 ml/min).
Adverse effects
Rare, serious side effects that would require immediate medical attention include:
- chills, infection
- dark urine, decreased urination (oliguria)
- difficulty swallowing or breathing, allergic reaction (anaphylaxis)
- hoarseness
- itching
- rapid weight gain, stomach pain
- yellowing of skin or eyes (jaundice)
Less severe side effects of moderate concern include:
- abdominal pain, bloating, vomiting
- chest pain or tightness, dizziness, lightheadedness, fainting (syncope)
- fever
- joint pain
- rash
The following side effects are common and likely to improve with time:
- cough
- diarrhea, loss of taste, nausea
- drowsiness, headache, tiredness
Lisinopril causes the kidneys to retain potassium, which may lead to hyperkalemia.
History/brand names
Lisinopril was developed by Merck & Co. and is marketed worldwide as Prinivil or Tensopril and by AstraZeneca as Zestril. In India it is marketed by Micro Labs as Hipril. Like other ACE inhibitors, it is derived from the venom of the jararaca, a Brazilian pit viper (Bothrops jararaca).
References
- Bussien JP, Waeber B, Nussberger J, Gomez HJ, Brunner HR. Once-daily lisinopril in hypertensive patients: Effect on blood pressure and the renin-angiotensin system. Curr Therap Res 1985;37:342-51.
- Lisinopril info - rx-list.com
- Goodman & Gilman's : The pharmacological basis of therapeutics, 10th. ed., 2001
- Lisinopril.com - Lisinopril information
Footnotes
- ^ Patchett A, Harris E, Tristram E, Wyvratt M, Wu M, Taub D, Peterson E, Ikeler T, ten Broeke J, Payne L, Ondeyka D, Thorsett E, Greenlee W, Lohr N, Hoffsommer R, Joshua H, Ruyle W, Rothrock J, Aster S, Maycock A, Robinson F, Hirschmann R, Sweet C, Ulm E, Gross D, Vassil T, Stone C (1980). "A new class of angiotensin-converting enzyme inhibitors". Nature 288 (5788): 280–3. doi:. PMID 6253826.
External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
See also
|
|||||||||||
Wikipedia content modification information:
- This page was last modified on 19 July 2008, at 14:20.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Lisinopril".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.